TOLMAR PHARMACEUTICALS INC

Tolmar Pharmaceuticals Inc. specializes in the manufacturing of pharmaceutical preparations, with a demonstrated focus on producing drugs, hematological agents, and related therapeutics for federal healthcare systems. Their technical expertise lies in GMP-compliant formulation, aseptic processing, and the scalable production of specialty pharmaceuticals, particularly those supporting chronic disease management and blood-related therapies. The company’s capability centers on end-to-end drug manufacturing, including active pharmaceutical ingredient integration, quality control protocols, and regulatory documentation aligned with FDA standards. Their precision in delivering complex drug formulations positions them as a niche supplier for mission-critical therapeutics requiring strict batch consistency and stability validation. The Department of Veterans Affairs is the sole federal agency with whom Tolmar Pharmaceuticals has a documented contractual relationship, indicating a targeted engagement in supplying pharmaceuticals through the Federal Supply Schedule for veteran healthcare programs. This relationship suggests alignment with VA’s priorities in accessible, high-quality medications for conditions prevalent among veteran populations, such as anemia, clotting disorders, and immunosuppressive therapies. The company’s primary industry focus is in NAICS 325412 — Pharmaceutical Preparation Manufacturing — where they operate as a specialized producer of finished dosage forms rather than bulk chemicals. Their market positioning is that of a reliable, small-scale manufacturer serving federal medical supply chains requiring reliable, regulated drug production without mass-market volume expectations. Tolmar Pharmaceuticals Inc. operates as a private pharmaceutical manufacturer with no publicly disclosed certifications or federal business classifications. The company maintains a focused geographic presence, likely centered on facilities compliant with federal drug manufacturing regulations, and holds a strategic niche within the government’s specialty pharmaceutical procurement ecosystem.